Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib in Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
NCT05727176Phase 2Recruiting
- Sponsor
- Taiho Oncology
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 2 trial of futibatinib in cholangiocarcinoma (CCA), sponsored by Taiho Oncology. Started Jul 2023; status: recruiting.
02
Drugs
futibatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05727176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727176.